Business
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
Company launches bold rebrand of Jeuveau® (prabotulinumtoxinA-xvfs), a modern-made neurotoxin dedicated exclusively for aesthetics Jeuveau® has been the
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"\n\nCompany launches bold rebrand of Jeuveau® (prabotulinumtoxinA-xvfs), a modern-made neurotoxin dedicated exclusively for aesthetics\n\n\n\nJeuveau® has been the fastest-growing neurotoxin in the U.S. for two consecutive years in 2021 and 20221\n\n\n\n NEWPORT BEACH, Calif.--(BUSINESS WIRE)--\nEvolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, unveils fresh, new branding for its flagship neurotoxin product, Jeuveau® (prabotulinumtoxinA-xvfs), showcased in the brand’s marketing campaign and on Jeuveau.com. Jeuveau® stands as the single most successful new aesthetic product launched in the United States since 2019 and intends to continue this trajectory, re-branding to break further away from the outdated tone, look and feel traditionally seen in the neurotoxin market.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230807151781/en/(Graphic: Evolus)\nThe new Jeuveau® imagery reflects today’s consumers, rejecting the traditional female-focused archetype, and celebrates the spectrum of beauty represented within the product’s growing contingent of loyal consumers – many of whom are millennials and younger. Inspired by this demographic, as well as the growing number of men turning to treatments to achieve a youthful, toned, and vibrant aesthetic, the “Jeuveau®, You See Me” marketing campaign uses inclusive messaging to encourage consumers of all genders to live unapologetically and embrace their beauty.\n\n\n“We’re excited for the public to see the new look of Jeuveau®, which reflects the attributes of the evolving clientele for toxins,” said David Moatazedi, President and CEO of Evolus. “We are immensely proud of the patient satisfaction that Jeuveau® has delivered since 2019 – largely due to delivering excellent product performance to the ever-changing market that is looking for a brand that’s reflective of their needs. The rebranding of Jeuveau® is a significant part of our commitment to doing exactly that.”\n\n\nJeuveau® has an estimated 11 percent of the current U.S. cosmetic neurotoxin market and is available in approximately 11,000 healthcare practitioner locations around the United States. The company recently achieved its one-millionth redemption in the Evolus Rewards™ patient loyalty pr...